Adjuvant Capecitabine the CREAT-X trial

CREAT-X, Capcetabine for Residual Cancer as Adjuvant Therapy trial is the first of it’s kind to look into further adjuvant chemotherapy in patients who received neoadjuvant chemotherapy.

Capecitabine adjuvant therapy is beneficial in Her2-negative Breast cancer with residual disease following Neoadjuvant therapy.

 

Continue reading “Adjuvant Capecitabine the CREAT-X trial”